Stay updated on Seagen Press Releases

Sign up to get notified when there's something new on the Seagen Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Seagen Press Releases page

  1. Check
    today
    Change Detected
    Summary
    Adds a 2025-2026 COVID-19 vaccine topline data item, a September 2025 date, and an Accessibility Statement; removes the Pfizer BRAFTOVI oncology press release. Overall, the page moves toward vaccine news and policy content rather than oncology drug news.
    Difference
    15%
    Check dated 2025-09-14T19:58:43.000Z thumbnail image
  2. Check
    8 days ago
    No Change Detected
  3. Check
    15 days ago
    Change Detected
    Summary
    The page now includes the FDA approval of Pfizer and BioNTech’s COMIRNATY® vaccine for specific age groups, while the previous mention of Astellas and Pfizer’s XTANDI™ research has been removed.
    Difference
    15%
    Check dated 2025-08-31T12:09:25.000Z thumbnail image
  4. Check
    22 days ago
    No Change Detected
  5. Check
    29 days ago
    Change Detected
    Summary
    The page now includes information about the significant survival benefits of PADCEV™ Plus KEYTRUDA™ for bladder cancer patients, while a previous announcement regarding Pfizer's licensing agreement has been removed.
    Difference
    12%
    Check dated 2025-08-17T04:35:27.000Z thumbnail image
  6. Check
    36 days ago
    Change Detected
    Summary
    The webpage has updated its financial reporting for Pfizer, replacing the first-quarter results with stronger second-quarter results and an increased EPS guidance for 2025.
    Difference
    9%
    Check dated 2025-08-10T00:28:45.000Z thumbnail image
  7. Check
    52 days ago
    Change Detected
    Summary
    The webpage has added significant updates regarding Pfizer's licensing agreement and a positive opinion for a COVID-19 vaccine, while removing older announcements about shareholder meeting results and research findings.
    Difference
    23%
    Check dated 2025-07-25T13:54:02.000Z thumbnail image
  8. Check
    66 days ago
    Change Detected
    Summary
    The page now includes a significant addition regarding the survival outcomes of XTANDI® Plus Leuprolide for a specific cancer treatment, while a previous financial update about Pfizer's dividend has been removed.
    Difference
    12%
    Check dated 2025-07-11T07:12:04.000Z thumbnail image

Stay in the know with updates to Seagen Press Releases

Enter your email address, and we'll notify you when there's something new on the Seagen Press Releases page.